Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus–Positive Patients: Incidence and Associated Factors

Sung-Hsi Huang,1,2 Chung-Hao Huang,3 Ning-Chi Wang,4 Tun-Chieh Chen,3,5 Yuan-Ti Lee,6,7 Shih-Ping Lin,8 Te-Yu Lin,4 Chi-Ying Lin,9 Yu-Lin Lee,10 Chen-Hsiang Lee,11 Cheng-Pin Chen,12 Kuan-Yin Chen,9 Chun-Eng Liu,10 Shu-Hsing Cheng,14,12 Po-Liang Lu,3 Chia-Jui Yang,15,16 and Chien-Ching Hung17 on behalf of the Taiwan HIV Study Group

Serological responses (Seroresponse) and durability of hepatitis A virus (HAV) vaccination are reduced among human immunodeficiency virus (HIV)-positive patients. Incidence of and associated factors with early seroreversion (loss of seroresponse) among HIV-positive patients who have achieved seroresponses after two doses of HAV vaccination remain unclear. In this multicenter study, we followed HIV-positive adults who had mounted seroresponses after completing two doses of HAV vaccination during a recent outbreak of acute hepatitis A between 2015 and 2017, a 1:4 case-control study was conducted to identify factors associated with seroreversion. Case patients were those with seroreversion, and controls were those with similar follow-up durations who were able to maintain seroresponses. During the study period, 49 of the 1,256 patients (3.9%) seroreverted after a median follow-up of 611 days. In a case-control study, seroreversion was more likely to occur in patients with a higher weight (adjusted odds ratio [aOR], 1.703; 95% confidence interval [CI], 1.292-2.323, per 10-kg increment) and HIV viremia at the time of vaccination (aOR, 2.922; 95% CI, 1.067-7.924), whereas positive seroresponse at 6 months of HAV vaccination and higher CD4 lymphocyte counts at vaccination were inversely associated with early seroreversion with an aOR of 0.059 (95% CI, 0.020-0.154) and 0.837 (95% CI, 0.704-0.979, per 100-cell/mm³ increment), respectively, in multivariable analyses. Conclusion: During an outbreak setting, early seroreversion following two-dose HAV vaccination occurred in 3.9% of HIV-positive patients. Lower and delayed seroresponses to HAV vaccination, a higher weight, and HIV viremia and lower CD4 lymphocyte counts at the time of HAV vaccination were associated with early seroreversion. Regular monitoring of seroresponse and booster vaccination might be warranted, especially in HIV-positive adults with predictors of early seroreversion. (Hepatology 2019;70:465-475).

Hepatitis A virus (HAV) is an important cause of viral hepatitis worldwide.1) Although commonly perceived as a food-borne, self-limited infection, recent outbreaks of acute hepatitis A (AHA) involving more than 4,000 patients who were mostly men who have sex with men...
Huang et al. Hepatology, August 2019

(MSM) in Europe and the Americas highlighted its potential as a contagious sexually transmitted disease in high-income countries\(^{2-4}\). In the United States, a recent large outbreak of AHA centered in homeless people and injecting drug users and resulted in 1,521 cases, 1,073 admissions, and 41 deaths.\(^{5}\) In addition to the public health threats to the at-risk populations, the economic losses from AHA outbreaks could also be substantial.\(^{6}\)

Since 1992, HAV vaccines that are safe, immunogenic, and highly effective in the prevention of HAV infection have become available. In healthy individuals, two doses of HAV vaccination administered 6-12 months apart induce protective antibodies in 95%-100% of vaccinees,\(^{7,8}\) which may last for at least 20 and 25 years in the long-term follow-up studies and mathematical models, respectively.\(^{9}\) Among individuals infected with human immunodeficiency virus (HIV), however, seroprotection generated by HAV vaccination has been shown to be less robust. After two doses of HAV vaccination, rates of seroconversion ranged from 48.6% to 94% and the geometric mean concentrations of protective anti-HAV antibodies are lower in individuals with HIV infection than in those without.\(^{10}\) Durability of serological response (seroreversion) to HAV vaccination in HIV-positive patients has also been a concern. In the general population, given its excellent immunogenicity and durability, booster doses after primary HAV vaccination are not recommended in most national and international guidelines\(^{11,12}\); however, for HIV-positive patients, most guidelines provide limited or no guidance on whether booster doses are needed,\(^{13,14}\) probably because there is a paucity of clinical evidence. Studies with small sample sizes have shown that 5%-20% of HIV-positive patients who had achieved seroresponses to HAV vaccination lost protective antibodies (seroreversion) within 18 months and 10%-25% within 5 years.\(^{15-17}\) Based on these observations, booster HAV vaccination every 10 years for HIV-positive patients with continuous risks of exposure is recommended by the British HIV Association.\(^{18}\)

Among the HIV-positive patients who lost their protective antibodies after successful primary HAV vaccination, several factors associated with seroreversion have been identified, which included higher plasma HIV-RNA load,\(^{17,19}\) hepatitis C virus (HCV) coinfection,\(^{15,16}\) absence of recent syphilis,\(^{15}\) and a longer duration of HIV infection.\(^{19}\) Understanding the predictors of HAV seroreversion after vaccination would inform the clinical guidance on serological monitoring and the need of subsequent booster HAV vaccination in the HIV-positive population. In the present study, we aimed to investigate the incidence of early seroreversion and explore its associated factors after having completed two-dose HAV vaccination.
among HIV-positive patients during an outbreak of AHA.

Participants and Methods

STUDY SETTING

In Taiwan, an unprecedented outbreak of AHA occurred among MSM between June 2015 and December 2017. To control the outbreak, an HAV vaccination campaign was launched in September 2015 and a subsidized HAV vaccination program was implemented in October 2016 among HIV-positive patients and those with sexually transmitted diseases. Following this large-scale HAV vaccination program among at-risk populations, high serological response rates to HAV vaccination were observed and HAV vaccination was effective in preventing AHA. Because of the supply shortage of HAVRIX 1440 enzyme-linked immunosorbent assay units (GlaxoSmithKline, Biologicals, Rixensart, Belgium) during the outbreak, it was gradually substituted by VAQTA 50 units (Merck and Co., Inc., West Point, PA) in the participating hospitals between May and October 2016.

This study was conducted at 11 designated hospitals for HIV care around Taiwan. In response to the outbreak of HAV in Taiwan since June 2015, HIV-positive patients who sought care in these hospitals were screened for anti-HAV antibodies and those who were seronegative were advised to receive two doses of HAV vaccine administered at 6 months apart. After vaccination, anti-HAV antibodies were determined at 4-24 weeks after the first dose and the second dose. For patients who successfully seroconverted following vaccination, anti-HAV antibodies were monitored every 6 months to evaluate durability of seroprotection following two doses of HAV vaccination.

HIV-related medical services, including combination antiretroviral therapy (cART) and monitoring of plasma HIV-RNA load and CD4 count, have been provided free of charge in the designated hospitals around Taiwan. Routine care for HIV-positive patients in the study hospitals included clinical assessment and determinations of immunological and virological status every 3-6 months and regular serological evaluations for hepatitis B, hepatitis C, and syphilis according to Taiwanese HIV treatment guidelines.

STUDY POPULATION AND PROCEDURE

This study population included patients aged at least 18 years who had received their first dose of HAV vaccine between June 2015 and June 2017, had positive anti-HAV antibodies after completion of two doses of HAV vaccination, and had follow-up measurements of anti-HAV antibodies more than 12 months after the first dose of HAV vaccination. Those who had received more than two doses of HAV vaccines or had AHA during the follow-up period were excluded.

We recorded demographics and clinical characteristics of patients, including age, sex, route for HIV transmission, use of tobacco, weight, height, use of cART, and serostatus of hepatitis B virus (HBV) and HCV. Overweight was defined by a body mass index (BMI) between 24 and 27 kg/m² and obesity by a BMI of greater than 27 kg/m² according to Taiwanese consensus. Plasma HIV-RNA loads and CD4 lymphocyte counts at nadir stage, time of HAV vaccination, and 1 year after the first dose of vaccination were recorded. Recent syphilis was defined as presence of symptoms or signs consistent with primary syphilis or secondary syphilis or a 4-fold increase from baseline in rapid plasma reagin (RPR) titers within 1 year after the first dose of HAV vaccination with a reactive Treponema pallidum particle agglutination (TPPA) test.

All patients were followed until occurrence of HAV seroreversion, loss to follow-up, or the end of this study on August 31, 2018, whichever occurred first. This retrospective study was approved by the research ethics committee or institutional review boards of the 11 participating hospitals, and informed consent was waived. The study was carried out in accord with the approved ethical guidelines and regulations.

CASE-CONTROL STUDY

A case patient with seroreversion, a seroconverter, was defined as an individual who lost his or her anti-HAV antibodies during the follow-up period, whereas a control, a nonseroconverter, was the one with persistently positive anti-HAV antibodies. After identification of seroconverters, we conducted a 1:4 matched case-control study to examine the associated factors with seroreversion. Controls were matched to case
patients by the month of first dose of HAV vaccination (±3 months), duration of follow-up (±3 months), and hospitals where the case patients were followed. If less than 4 controls could be identified within the same hospital, patients from a nearest hospital from the same region were matched instead. If more than 4 controls were available for matching, 4 controls were selected randomly by EXCEL software (version 15.27; Microsoft Corporation, Albuquerque, NM).

LABORATORY INVESTIGATIONS

During the study period, the determinations of plasma HIV-RNA load, CD4 lymphocyte count, and serological tests for syphilis, and hepatitis A, B, and C were performed using certified commercial test kits. Anti-HAV antibodies were determined by ARCHITECT HAV antibody (Ab) immunoglobulin G (IgG; Abbott, Weisbaden Germany), a semiquantitative chemiluminescence immunoassay (CLIA) with a cut-off signal-to-cut-off (S/CO) value of 1,22,24 in six hospitals; by Cobas Anti-HAV (Roche, Mannhein Germany), a quantitative electrochemiluminescence immunoassay (ECLIA) with a cut-off value of 20 IU/L and a detection range of 3-60 IU/L,27,28 in four hospitals; and by ADVIA Centaur HAV Total (Siemens Healthcare Diagnostics Inc., Tarrytown, NY), a competitive chemiluminometric immunoassay with a cut-off value of 20 IU/L and detection range of 0-100 IU/L in one hospital.29,30 Detection limits of the test kits for plasma HIV-RNA load were 20, 40, or 50 copies/mL at the participating hospitals.

STATISTICAL ANALYSIS

Statistical analyses were performed using R statistics software (version 3.3.2; R Foundation for Statistical Computing, Vienna, Austria). Noncategorical variables were compared using the Mann-Whitney U test, and categorical variables were compared using Fisher’s exact test. In the case-control study, variables with $P < 0.2$ were entered into a multivariable general linear regression model with backward selection and missing values treated by imputation with mean to identify factors associated with early HAV seroreversion and determine the adjusted odds ratio (aOR) of each variable. Before being entered into multivariable analysis, variables with apparent correlation, such as weight, BMI, and obesity, were compared and only the variable with the smallest $P$ value was selected into the model. A sensitivity analysis was carried out using another multivariable model that included only those matched patients from the hospitals using the CLIA method for determination of anti-HAV IgG titers. Variables with a $P$ value <0.05 were deemed statistically significant throughout the analyses.

Results

From June 2015 to June 2017, 2,183 HIV-positive adult patients who completed two doses of HAV vaccination had been seeking HIV care at the 11 hospitals and 1,923 (88.1%) had confirmed vaccine-induced seroconversion within 12 months. Among patients with seroresponses, 1,256 (65.3%) were included in this case-control study, which included 1,253 who had follow-up measurements of anti-HAV antibodies more than 1 year after the first dose of HAV vaccination and 3 who seroreverted within 12 months (Fig. 1). The majority of the included patients were MSM (98.6%) with a median age of 32 years (interquartile range [IQR], 28-38; Table 1). At the time of HAV vaccination, more than 95% of the study population were taking cART, 85.7% had achieved plasma HIV-RNA load to <50 copies/mL, and median CD4-lymphocyte count was 575 cells/mm$^3$ (IQR, 433-748). Following vaccination, 64.5% of vaccinees achieved seroresponses at month 6, before administration of the second dose. Overall, baseline characteristics of patients not included in this study were generally similar to those who were included, except that the former group of patients were more likely to be seropositive for HCV, to have received HAV vaccine later in the study period with a shorter follow-up duration, and to have had positive anti-HAV antibodies before the second dose of HAV vaccine (Supporting Table S1).

After a median follow-up of 611 days (IQR, 526-721) since the first dose of HAV vaccination, seroreversion of anti-HAV antibodies occurred in 49 (3.9%) of the included patients and in 6.8% of those with CD4 counts <350 cells/mm$^3$ (Supporting Table S2). The earliest seroreversion was observed at day 310 of the first dose of HAV vaccination, and half of the seroreverters lost their anti-HAV antibodies by day 549. Evolution of median anti-HAV antibody titers
measured by ARCHITECT HAV Ab IgG with time is illustrated in Fig. 2, which shows that antibody response started to decay early after completion of two doses of HAV vaccination in both seroreverters and nonseroreverters. Seroreverters mounted positive anti-HAV seroresponses later in the course, compared to nonseroreverters, and their peak anti-HAV titers were lower (Fig. 2).

In the case-control analysis, 196 controls who were able to maintain seroresponses following HAV vaccination were matched to 49 case patients with seroreversion. Clinical and laboratory characteristics of case patients and controls are shown in Table 2. The two groups were well matched in their timing of vaccination and follow-up durations. Compared to controls in the univariable analysis, case patients (seroreverters) had a higher weight (median, 72 vs. 66 kg; \( P = 0.001 \)) and BMI (median, 23.7 vs. 22.3 kg/m\(^2\); \( P = 0.003 \)), were more likely to be overweight or obese (47.7% vs. 29.8%; \( P = 0.032 \)), were less likely to have achieved HIV viral suppression at vaccination (71.4% vs. 85.2%; \( P = 0.034 \)), had a lower median CD4 lymphocyte count at vaccination (486 vs. 576 cells/mm\(^3\); \( P = 0.024 \)), were less likely to have achieved seroresponses before the second dose of HAV vaccination (5.5% vs. 67.1%; \( P < 0.001 \)), and mounted lower peak anti-HAV titers (\( P < 0.001 \)) whether determined by CLIA or other quantitative methods (Table 2).

Weight, use of cART, HIV-RNA load >200 copies/mL, and CD4 lymphocyte counts at the time of HAV vaccination and positive anti-HAV seroresponse at 6 months were entered into the multivariable analysis. Peak anti-HAV titers were not included because values from different test methods were not directly comparable. In the model, early seroreversion was more likely to occur in patients with a higher weight (aOR, 1.703; 95%
CI, 1.292-2.323, per 10-kg increment) and those with plasma HIV-RNA load >200 copies/mL at the time of vaccination (aOR, 2.922; 95% CI, 1.067-7.924), whereas positive anti-HAV seroresponse at 6 months and higher CD4 lymphocyte counts at vaccination were inversely associated with early seroreversion with an aOR of 0.059 (95% CI, 0.020-0.154) and 0.837 (95% CI, 0.704-0.979, per 100-cell/mm³ increment), respectively (Table 3).

A sensitivity analysis including only the patients whose anti-HAV titers were determined by ARCHITECT HAV Ab IgG showed that the most significant factor associated with early seroreversion was peak anti-HAV titers. The rest of the findings were similar to the primary analysis, except that in this model the association between seroreversion and CD4 lymphocyte counts at time of vaccination was no longer statistically significant (Supporting Table S3).

Discussion

In this study, we identified a cohort of HIV-positive adult patients who successfully seroconverted after completing the standard two doses of HAV vaccination and found a seroreversion rate of 3.9% after a median duration of 1.7 years. To our knowledge, this is the largest longitudinal follow-up study to date that focuses on HAV seroreversion among HIV-positive patients. A higher weight, plasma HIV-RNA load >200 copies/mL and lower CD4 lymphocyte counts at the time of vaccination, and lower peak anti-HAV titers and lack of anti-HAV seroresponse before the second dose of HAV vaccination were independently associated with higher odds for HAV seroreversion.

Durability of responses to vaccination has been a concern among HIV-positive patients because of their impaired immunity compared to HIV-negative individuals. (31) Although seroreversion cannot be translated directly into loss of protection, as shown in the anamnestic response after hepatitis B vaccination, (32,33) AHA in HIV-positive individuals who had had positive anti-HAV antibodies has been reported, (34) indicating that loss of seroprotective antibodies may lead to susceptibility to hepatitis A infection in the HIV-positive population. Several studies reported a substantial rate of loss of HAV antibodies after vaccine-induced seroconversion. (15,16,19) Launay et al. and

| TABLE 1. Characteristics of the 1,256 Included Patients |
|---------------------------------------------------------|
| Age, medium (IQR), years                                | 32 (28, 38) |
| Male, n (%)                                             | 1,238 (98.6) |
| MSM, n (%) (N = 1,222)                                  | 1,177 (96.3) |
| Weight, median (IQR), kg (N = 1,154)                    | 66 (60.74) |
| BMI, median (IQR) (N = 993)                             | 22.4 (20.4, 24.7) |
| Overweight or obesity*, n (%)                           | 312 (31.4) |
| Obesity*, n (%)                                         | 112 (11.3) |
| Use of CART, n (%)                                      | 123 (9.8) |
| At the first dose of HAV vaccination                     | 1,194 (95.1) |
| At month 6 of vaccination                               | 1,236 (98.4) |
| Viral hepatitis coinfection, n (%)                      | 123 (9.8) |
| Anti-HCV positive (N = 1,255)                           | 65 (5.2) |
| Recent syphilis†, n (%)                                 | 288 (22.9) |
| Current smoker, n (%) (N=1128)                          | 305 (27.0) |
| Plasma HIV-RNA load at vaccination                      | 180 (14.3) |
| HIV-RNA load >50 copies/mL, n (%)                       | 119 (9.5) |
| Plasma HIV-RNA load at month 12 (N = 1,249)             | 47 (3.8) |
| HIV-RNA load >50 copies/mL, n (%)                       | 23 (1.8) |
| Nadir CD4 count, median (IQR), cells/mm³ (N = 1,194)    | 292 (154, 413) |
| CD4 count at vaccination, median (IQR), cells/mm³ (N = 1,255) | 395 (33.1) |
| CD4 count at vaccination, median (IQR), cells/mm³ (N = 1,255) | 29 (2.3) |
| CD4 count at month 12 (M12), median (IQR), cells/mm³  | 636 (496, 815) |
| CD4 count at M12 <100 cells/mm³, n (%)                  | 14 (1.1) |
| Date of vaccination, n (%)                              | 541 (43.1) |
| Before June 30, 2016                                    | 715 (56.9) |
| After July 1, 2016                                      | 950 (75.6) |
| Brand of the first dose of HAV vaccine, n (%)           | 306 (24.4) |
| Havrix                                                 | 15 (1.2) |
| Vaqta                                                  | 1,241 (98.8) |
| Brand of the second dose of HAV vaccine, n (%)          | 587 (64.5) |
| Peak anti-HAV lgG titer, median (IQR)                   | 10.35 (8.35, 12.03) |
| By ARCHITECT HAV Ab lgG, S/CO (N = 799)                 | >60 (>60, >60) |
| By Cobas Anti-HAV and ADVIA Centaur HAV Total, IU/L (N = 395) | Follow-up duration, median (IQR), days after the first dose of HAV vaccination | 611 (526, 721) |

*Overweight was defined by a BMI between 24 and 27 kg/m² and obesity by BMI of 27 kg/m² or greater.
†Recent syphilis was defined by presence of symptoms or signs consistent with primary syphilis or secondary syphilis, or a 4-fold increase from baseline in RPR titer with a reactive TPPA test within 1 year after the first dose of HAV vaccination.
Abbreviation: HBsAg, hepatitis B surface antigen.
Cheng et al., in their previous investigations, found that, at 18 months after vaccination, seroreversion rates were 6% and 13%, respectively.\textsuperscript{(15,35)} By comparison, the seroreversion rate in our study was a little bit lower, which may be reassuring in an outbreak setting. The retrospective design of our study of a shorter observation duration and the natural booster effect that might occur during an ongoing HAV outbreak may have contributed to the discrepancies observed. Another potential explanation could be that the population in our study was mostly virally suppressed and had higher baseline CD4 lymphocyte counts compared to those included in the previous studies.\textsuperscript{(15-17)} Of note, the sample size of the current study was 5 times as large as the two previously mentioned studies combined.

Measurements of antibody titers are the most common method to evaluate the host responses to vaccination and have been used as surrogate markers of clinical endpoints in many vaccine trials.\textsuperscript{(36,37)} It is not unexpected that a lower peak anti-HAV antibody titer after vaccination was associated with early seroreversion in this study. Unfortunately, anti-HAV antibody measurements used in this study were not standardized. Most of the participating hospitals utilized a semiquantitative CLIA method to measure anti-HAV IgG, whereas the other hospitals used quantitative CLIA and ECLIA kits to measure total anti-HAV antibody titers with detection limits only up to 60 and 100 IU/L. This could potentially limit the clinical implication of our study, because meaningful cut-off values of anti-HAV titers to predict

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|c|c|c|}
\hline
Duration after first dose of HAV vaccine (month) & 1 & 6 & 7 & 12 & 12-18 & 18-24 & 24-30 \\
\hline
Non-seroreverter, n & 576 & 570 & 590 & 557 & 434 & 490 & 251 \\
\hline
Seroreverter, n & 28 & 24 & 31 & 25 & 23 & 15 & 6 \\
\hline
\end{tabular}
\caption{Evolution of serological responses after HAV vaccination in HIV-positive patients according to their status of seroreversion. Seroreverters were less likely to mount anti-HAV IgG responses before the second dose of HAV vaccination (month 6) had lower peak anti-HAV IgG titers after completion of two doses of vaccination.}
\end{table}
early seroreversion cannot be analyzed from the data collected. Nevertheless, a positive anti-HAV seroresponse before the second dose of HAV vaccination can be a useful tool for clinical follow-ups. As expected, patients with no seroresponse before administration of the second dose of HAV vaccine were more likely to lose seroprotective antibodies early in the course.

Detectable or higher plasma HIV-RNA load at time of vaccination or time of follow-up of antibody response has been reported in several studies.

### Table 2. Case-Control Analysis of Factors Associated With Early Seroreversion After HAV Vaccination

| Feature                                                                 | Seroreverters | Nonseroreverters | PValue |
|------------------------------------------------------------------------|--------------|-----------------|--------|
| **Age, median (IQR), years**                                           | 34 (29, 39)  | 33 (28, 39)     | 0.331  |
| **Male, n (%)**                                                        | 49 (100)     | 194 (99.0)      | >0.999 |
| **MSM, n (%) (N = 241)**                                               | 48/49 (98.0) | 185/192 (96.4)  | >0.999 |
| **Weight, median (IQR), kg (N = 225)**                                 | 72 (62, 85)  | 66 (58, 73)     | 0.001  |
| **BMI, median (IQR), (N = 215)**                                       | 23.7 (21.2, 27.0) | 22.3 (20.1, 24.5) | 0.003  |
| **Overweight or obesity*, n (%)**                                      | 21/44 (47.7) | 51/171 (29.8)   | 0.032  |
| **Obesity*, n (%)**                                                    | 11/44 (25.0) | 14/171 (8.2)    | 0.006  |
| **Use of cART, n (%)**                                                 |              |                 |        |
| At the first dose of HAV vaccination                                   | 43 (87.8)    | 185 (94.4)      | 0.117  |
| At month 6 of vaccination                                              | 49 (100)     | 195 (99.5)      | >0.999 |
| **Viral hepatitis coinfection, n (%)**                                 |              |                 |        |
| HBsAg positive                                                        | 4 (8.2)      | 18 (9.2)        | >0.999 |
| Anti-HCV positive                                                      | 3 (6.1)      | 11 (5.6)        | >0.999 |
| **Recent syphilis†, n (%) (N = 230)**                                   | 14 (28.6)    | 47 (24.0)       | 0.580  |
| **Current smoker, n (%) (N = 230)**                                    |              |                 |        |
| HIV-RNA load >50 copies/mL, n (%)                                      | 14 (28.6)    | 29 (14.8)       | 0.034  |
| HIV-RNA load >200 copies/mL, n (%)                                     | 11 (22.4)    | 18 (9.2)        | 0.023  |
| **Plasma HIV-RNA load at month 12**                                    |              |                 |        |
| HIV-RNA load >50 copies/mL, n (%)                                      | 4 (8.2)      | 7 (3.6)         | 0.238  |
| HIV-RNA load >200 copies/mL, n (%)                                     | 1 (2.0)      | 3 (1.5)         | >0.999 |
| **Nadir CD4 count, median (IQR), cells/mm³ (N = 234)**                 | 264 (153, 431)| 304 (145, 453)  | 0.615  |
| **Nadir CD4 <200 cells/mm³, n (%)**                                    | 16/49 (32.7) | 67/185 (36.2)   | 0.738  |
| **CD4 count at vaccination, median (IQR), cells/mm³**                  | 486 (394, 662)| 576 (452, 760)  | 0.024  |
| **CD4 at vaccination <200 cells/mm³, n (%)**                           | 2 (4.1)      | 4 (2.0)         | 0.345  |
| **CD4 count at month 12 (M12), median (IQR), cells/mm³**               | 606 (444, 842)| 639 (489, 834)  | 0.498  |
| **CD4 at M12 <200 cells/mm³, n (%)**                                   | 1 (2.0)      | 3 (1.5)         | >0.999 |
| **Date of vaccination, n (%)**                                         |              |                 | >0.999 |
| Before June 30, 2016                                                   | 26 (53.1)    | 104 (53.1)      |        |
| After July 1, 2016                                                    | 23 (46.9)    | 92 (46.9)       |        |
| **Brand of the first dose of HAV vaccine, n (%)**                      |              |                 | 0.325  |
| Havrix                                                                | 21 (42.9)    | 69 (35.2)       |        |
| Vaqta                                                                 | 28 (57.1)    | 127 (64.8)      |        |
| **Positive anti-HAV IgG at month 6, n (%) (N = 185)**                   | 2/36 (5.5)   | 100/149 (67.1)  | <0.001 |
| **Peak anti-HAV IgG titer, median (IQR)**                              | 3.15 (2.50, 5.06)| 10.89 (8.60, 11.99)| <0.001 |
| By ARCHITECT HAV Ab IgG, S/CO (N = 166)                                 | 38.44 (32.94, 57.28)| >60 (>60, >60) | <0.001 |
| By Cobas Anti-HAV, IU/L (N = 79)                                       | 3.15 (2.50, 5.06)| 10.89 (8.60, 11.99)| <0.001 |
| **Duration of follow-up, median (IQR), days after first dose of HAV vaccination** | 549 (450, 648) | 566 (489, 665) | 0.291  |

*Overweight was defined by a BMI between 24 and 27 kg/m² and obesity by BMI of 27 kg/m² or greater.

†Recent syphilis was defined by presence of symptoms or signs compatible with primary syphilis or secondary syphilis, or a 4-fold increase from baseline in RPR titer with a reactive TPPA test within 1 year after the first dose of HAV vaccination.

Abbreviation: HBsAg, hepatitis B surface antigen.
including ours, to be associated with poorer HAV vaccine durability.\(^{(17,19)}\) Similar findings were also reported in HBV vaccination studies.\(^{(38)}\) Higher baseline CD4 lymphocyte counts have been shown to be associated with primary HAV vaccine seroresponse in many studies.\(^{(39)}\) The present study suggests that the correlation also existed between levels of CD4 cell counts and durability of seroresponse to HAV vaccination. Although the exact mechanism behind these phenomena warrants further investigations, these findings have been suggested to be related to a quantitative and functional decline in activated T cells among HIV-positive patients despite cART.\(^{(38)}\)

Correlation between obesity and poorer vaccine response had been reported in studies of hepatitis B, tetanus, and rabies vaccines.\(^{(40,41)}\) In this study, patients with higher weights had higher odds for early seroreversion after HAV vaccination, and seroreversion rates increased from 6.3% in patients with a weight of 70 kg or higher to 23.8% in those with a weight of 100 kg or higher (Supporting Table S4). Two studies of HAV vaccination in nonimmunocompromised subjects also demonstrated a slower and lower seroresponse after vaccination among those with higher BMI.\(^{(42,43)}\) This poorer seroresponse resulted in delayed seroconversion and lower antibody titers, which could explain the association between the higher weight and early HAV seroreversion observed in the present study. It has been postulated that the adipose tissue and inflammatory cytokines and hormones produced could induce a chronic state of inflammation and interfere with proper vaccine-induce immune response.\(^{(41)}\) Exact mechanisms by which obesity affects our adaptive immune responses are yet to be elucidated.

Specific sexually transmitted diseases, including syphilis and HCV infection, have been proposed as surrogate markers of higher-risk sexual behavior\(^{(22)}\) and shown to be associated with better durability of seroresponse to HAV vaccination\(^{(15,16)}\) because of higher chance to confer natural booster through new risky exposures. This was not found in the present study, however. Because this is a vaccine durability study taking place in a setting of AHA outbreak, we suspected the background circulating HAV natural boosters might occur irrespective of higher-risk sexual behaviors, though the rate of recent syphilis observed were similar between seroreverters and nonseroreverters. The link between high-risk sexual behaviors and persistence of anti-HAV seroresponse will need further clarification in a nonoutbreak setting.

The HAV vaccines administered in this study included two different brands (HAVRIX and VAQTA), and this could potentially affect vaccine response. Most of the included vaccinees received HAVRIX-VAQTA or VAQTA-VAQTA, and our previous analysis showed comparable serological response between the two combinations at 48 weeks.\(^{(24)}\) The current analysis did not detect any association between vaccine brands received and early seroreversion, which further supports their comparability in the short term. However, whether different combinations of vaccines would result in different durability of vaccine responses in the long-term follow-up remains to be investigated.

Despite well-documented effectiveness of hepatitis A vaccination, coverage among people living with HIV remains poor in many parts of the world.\(^{(44)}\) Also, the lack of monitoring of serological response after vaccination to evaluate the need for repeated or booster vaccination among HIV-positive individuals could result in a substantial number of susceptible hosts and the subsequent persistence of HAV transmission in communities. The impact would be even more significant in countries where obesity and suboptimal control of HIV infection are prevalent, according to the findings of the present study. More studies to investigate the optimal timing for follow-up of seroresponse after HAV vaccination and booster vaccination are urgently needed to inform the current guidelines. In the recent study conducted during the outbreak of AHA, we found that HIV-positive patients who had lost their anti-HAV antibodies after primary vaccination could mount rapid and robust seroresponses to one single-dose HAV vaccination.\(^{(45)}\)

### TABLE 3. Multivariable Analysis of Factors Associated With Early Seroreversion After HAV Vaccination

| Factor                                      | aOR     | P Value |
|---------------------------------------------|---------|---------|
| Weight, per 10-kg increment                 | 1.703(1.292-2.323) | <0.001 |
| HIV-RNA load >200 copies/mL at vaccination  | 2.922(1.067-7.924) | 0.035  |
| CD4 count at vaccination, per 100-cell/mm\(^3\) increment | 0.837(0.704-0.979) | 0.034  |
| Positive anti-HAV at month 6                | 0.059(0.020-0.154) | <0.001 |
of our study results. First, selection bias is expected from the retrospective design of this study, because only those patients with follow-up of seroresponses were included in this study. Indeed, approximately one third of patients who had completed two doses of HAV vaccination with seroresponse were not included because they did not have anti-HAV antibodies measured after 12 months. These patients received HAV vaccines later in the study period, close to the end of the AHA outbreak, and thus they were probably less likely to experience natural booster. Second, the majority of the included patients were males, who had been receiving successful cART with HIV viral suppression. Cautions should be exercised to generalize our results to female HIV-positive patients, those who have not initiated cART, or those who experienced virological failure.

In conclusion, we found a low, but substantial, rate of early seroreversion among HIV-positive patients after two doses of HAV vaccination. These patients were more likely to serorevert if they had higher weights, had detectable plasma HIV RNA loads or lower CD4 lymphocyte counts at the time of vaccination, or had lower peak anti-HAV antibody titers and negative anti-HAV antibodies before the second dose of HAV vaccination. Regular monitoring of seroresponse and booster vaccination after primary HAV vaccination is warranted, especially in these subsets of HIV-positive patients.

REFERENCES

1) World Health Organization. The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review. Geneva, Switzerland: World Health Organization; 2009.
2) Ndumbi P, Freidl GS, Williams CJ, Mårdh O, Varela C, Avellón A, et al.; Members of the European Hepatitis A Outbreak Investigation Team. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017. Euro Surveill 2018;23:85.
3) Barreiro P, Soriano V. Hepatitis A outbreaks in European homosexual men. AIDS Rev 2017;19:113-114.
4) Latash J, Dorsinville M, Del Rosso P, Antwi M, Reddy V, Waechter H, et al. Notes from the field: increase in reported hepatitis A infections among men who have sex with men—New York City, January-August 2017. MMWR Morb Mortal Wkly Rep 2017;66:999-1000.
5) Foster M, Ramachandran S, Myatt K, Donovan D, Bohm S, Fiedler J, et al. Hepatitis A virus outbreaks associated with drug use and homelessness—California, Kentucky, Michigan, and Utah, 2017. MMWR Morb Mortal Wkly Rep 2018;67:1208-1210.
6) Sansom SL, Cotter SM, Smith F, Koch E, de Fijter S, Long T, et al. Costs of a hepatitis A outbreak affecting homosexual men: Franklin County, Ohio, 1999. Am J Prev Med 2003;25:343-346.
7) Levy MJ, Herrera JL, DiPalma JA. Immune globulin and vaccine therapy to prevent hepatitis A infection. Am J Med 1998;105:416-423.
8) Irving GJ, Holden J, Yang R, Pope D. Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev 2012;10:S159.
9) Theeten H, Van Heerck K, Van Der Meerlen O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 2015;33:5723-5727.
10) Lin KY, Chen GJ, Lee YL, Huang YC, Cheng A, Sun HY, et al. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: a review. World J Gastroenterol 2017;23:3589-3606.
11) Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-23.
12) World Health Organization. Hepatitis A [Internet]. World Health Organization. International travel and health, Geneva, Switzerland: World Health Organization; 2012. http://www.who.int/ith/vaccines/hepatitisA/en/. Accessed November 24, 2018.
13) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2018. https://aidsinfo.nih.gov/guidelines. Accessed November 20, 2018.
14) European AIDS Clinical Society. EACS treatment guideline 2018. 2018. http://www.eacsociety.org/files/2018_guideline-9.1-english.pdf. Accessed November 20, 2018.
15) Cheng A, Chang SY, Sun HY, Tsai MS, Liu WC, Su YC, et al. Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in human immunodeficiency virus-positive adults on antiretroviral therapy. J Infect Dis 2017;215:606-613.
16) Jablonowska E, Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int J STD AIDS 2014;25:745-750.
17) HuaNg et al. Hepatology, August 2019
18) British HIV Association. British HIV association guidelines on the use of vaccines in HIV-positive adults 2015. 2015. http://www.bhiva.org/documents/Guidelines/Immunisation/consultation/BHIVA-Immunisation-Guidelines-2015-Consultation.pdf. Accessed June 12, 2018.
19) Kernéis S, Desaint C, Brichler S, Rey D, Belarbi L, Gondien E, et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr 2011;57:e63-e66.
20) Lee YL, Chen GJ, Chen NY, Liou BH, Wang NC, Lee YT, et al. Less severe but prolonged course of acute hepatitis A in HIV-positive patients than HIV-negative patients during an outbreak: a multicenter observational study. Clin Infect Dis 2018;28:47.
21) Chen GJ, Lin KY, Sun HY, Sheng WH, Hsiieh SM, Huang YC, et al. Incidence of acute hepatitis A among HIV-positive patients during an outbreak among MSM in Taiwan: Impact of HAV vaccination. Liver Int 2018;38:594-601.
22) Lin KY, Hsieh SM, Sun HY, Lo YC, Sheng WH, Chuang YC, et al. Serologic responses and effectiveness of hepatitis A vaccination among human immunodeficiency virus-positive individuals during the outbreak of acute hepatitis A. Hepatology 2018;12:e1001923.

23) Chen GJ, Lin KY, Hung CC, Chang SC. Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection. J Infect Dis 2018;215:1339-1340.

24) Lin KY, Hsieh SM, Sheng WH, Lo YC, Chuang YC, Cheng A, et al. Comparable serologic responses to 2 different combinations of inactivated HAV vaccines in HIV-positive patients during the acute hepatitis A outbreak in Taiwan. J Infect Dis 2018;215:734-738.

25) Lin KY, Cheng CY, Li CW, Yang CJ, Tsai MS, Liu CE, et al. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS One 2017;12:e0197897.

26) Chang HC, Yang HC, Chang HY, Yeh CJ, Chen HH, Huang KC, et al. Morbid obesity in Taiwan: Prevalence, trends, associated social demographics, and lifestyle factors. PLoS One 2017;12:e0169577.

27) Espul C, Benedetti L, Linares M, Cuello H, Castro Lo I, Thollot Y, et al. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Hum Vaccin Immunother 2017;13:2707-2712.

28) Cobas ® Anti-HAV (Package insert). Indianapolis, IN: Roche Diagnostics; April 2017.

29) ADVIA Centaur® HAV Total (Package insert). Norwood, MA: Siemens Healthcare Diagnostics Inc.; 2008.

30) Okrongly D. The ADVIA Centaur® immunoassay system—designed for infectious disease testing. J Clin Virol 2004;30:S18-S21.

31) Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58:1130-1139.

32) Giacomet V, Masetti M, Nannini P, Forlanini F, Clerici M, Zuccotti GV, et al. Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults. PLoS One 2018;13:e0192638.

33) Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008;197:1419-1426.

34) Lee MJ, Douthwaite S, Kulasegaram R. Acute hepatitis A infection after hepatitis A immunity in a HIV-positive individual. Sex Transm Infect 2018;94:30-31.

35) Launay O, Grabar S, Gordin E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPVAC study. J Acquir Immune Defic Syndr 2008;49:272-275.

36) World Health Organization. Correlates of vaccine-induced protection: methods and implications. Geneva, Switzerland: World Health Organization; 2013:1-65.

37) Zaccaro DJ, Wagener DK, Whisnant CC, Staats HF. Evaluation of vaccine-induced antibody responses: impact of new technologies. Vaccine 2013;31:2756-2761.

38) Powis JE, Raboud J, Ostrowski M, Loutfy MR, Kovacs C, Walmsley SL. The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection? J Infect Dis 2012;205:1534-1538.

39) Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology 2013;57:1734-1741.

40) Young KM, Gray CM, Bekker LG. Is obesity a risk factor for vaccine non-responsiveness? PLoS One 2013;8:e82779.

41) Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine 2015;33:4422-4429.

42) Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 1997;15:1157-1161.

43) Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006;24:5509-5515.

44) DeGroote NP, Mattson CL, Tie Y, Brooks JT, Garg S, Weiser J. Hepatitis A virus immunity and vaccination among at-risk persons receiving HIV medical care. Prev Med Rep 2018;11:139-144.

45) Chen GJ, Lin KY, Cheng A, Huang YC, Hsieh SM, et al. Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination. Liver Int 2018;38:1198-1205.

Author names in bold designate shared co-first authorship.